Johnson & Johnson JNJ
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Johnson & Johnson (JNJ) Business Model and Operations Summary
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Key Insights
Johnson & Johnson (JNJ) Core Market Data and Business Metrics
Latest Closing Price
$153.25Market Cap
$399.65 BillionAverage Daily Trade Volume
9,103,818 SharesPrice-Earnings Ratio
26.47Total Outstanding Shares
2.41 Billion SharesCEO
Mr. Joaquin DuatoTotal Employees
138,100Dividend
$1.24 Per Share QuarterlyIPO Date
January 2, 1943SIC Description
Pharmaceutical PreparationsPrimary Exchange
New York Stock ExchangeHeadquarters
One Johnson & Johnson Plz, New Brunswick, NJ, 08933
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 29, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $-3.13 Billion |
| Net Cash Flow From Operating Activities, Continuing | $24.27 Billion |
| Net Cash Flow From Operating Activities | $24.27 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-18.60 Billion |
| Net Cash Flow, Continuing | $2.54 Billion |
| Net Cash Flow From Investing Activities | $-18.60 Billion |
Income Statement
January 1, 2024 to December 29, 2024
| Metric | Value |
|---|---|
| Other Operating Expenses | $19.95 Billion |
| Research and Development | $1.84 Billion |
| Income Tax Expense/Benefit, Current | $4.80 Billion |
| Income/Loss From Continuing Operations Before Tax | $16.69 Billion |
| Income/Loss From Continuing Operations After Tax | $14.07 Billion |
| Diluted Earnings Per Share | $5.79 |
Comprehensive Income
January 1, 2024 to December 29, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $14.85 Billion |
| Other Comprehensive Income/Loss | $786 Million |
| Comprehensive Income/Loss | $14.85 Billion |
Balance Sheet
January 1, 2024 to December 29, 2024
| Metric | Value |
|---|---|
| Equity | $71.49 Billion |
| Other Non-current Assets | $66.08 Billion |
| Assets | $180.10 Billion |
| Noncurrent Assets | $124.21 Billion |
| Long-term Debt | $32.40 Billion |
| Accounts Payable | $10.31 Billion |
Historical Dividends
Current dividend: $1.24 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Jan 2, 2025 | Mar 4, 2025 | Feb 18, 2025 | $1.24 | Quarterly |
| Oct 15, 2024 | Dec 10, 2024 | Nov 26, 2024 | $1.24 | Quarterly |
| Jul 17, 2024 | Sep 10, 2024 | Aug 27, 2024 | $1.24 | Quarterly |
| Apr 16, 2024 | Jun 4, 2024 | May 21, 2024 | $1.24 | Quarterly |
| Jan 2, 2024 | Mar 5, 2024 | Feb 20, 2024 | $1.19 | Quarterly |
| Oct 19, 2023 | Dec 5, 2023 | Nov 21, 2023 | $1.19 | Quarterly |